IP Library Granted Patent US 12,201,742
Granted Patent B2
US 12,201,742 · App. 17/765,953 · Granted Jan 21, 2025

Hydrophobically-modified biopolymer materials

Inventor: Matthew Dowling (Riverdale, MD)
Assignee: MEDCURA, INC.
A61L24/08A61L24/0031A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,742
App. No.
17/765,953
Granted
Jan 21, 2025
Kind
B2
Abstract

In various aspects and embodiments, the present invention provides hemostatic products and methods for treating wounds, including cavity wounds and non-compressible hemorrhage. In various embodiments, the invention employs hydrophobically-modified polymer foams, gels, or pastes.

Claims (18)

1. A hemostatic product comprising a container having at least two compartments each containing a releasable, flowable product: wherein a first compartment comprises a solution having a concentration from about 0.1 wt % to about 5 wt % of an acidified hydrophobically-modified chitosan that creates hemostasis and has a pH of from about 2 to about 4.5, and a second compartment comprises a solution of a bicarbonate or carbonate salt at an alkaline pH, wherein the hydrophobic modifications of the chitosan comprise linear hydrocarbon groups in the range of C6 to C18.

2. The product of claim 1 , wherein the linear hydrocarbon groups are independently selected from C12, C14, and C16 hydrocarbon chains.

3. The product of claim 1 , comprising:

(a) grafts of C6 to C8 in length;

(b) grafts of C10 to C14 in length; and

(c) grafts of C16 to C18 in length.

4. The product of claim 3 , wherein the hydrocarbon groups comprise or consist essentially of C8, C12, and C16 hydrocarbon groups.

5. The product of claim 1 , wherein the hydrophobically-modified polymer has a grafting density from about 1% to about 50% of available functional groups on the polymer backbone.

6. The product of claim 5 , wherein the hydrocarbon groups have a grafting density of: about 3% to about 7% C8, about 1% to about 5% C12, and/or about 0.5% to about 3% C16, with respect to available amines.

7. The product of claim 1 , wherein one or more compartments comprise one or more foam stabilizing additives.

8. The product of claim 7 , wherein the foam stabilizing additives comprise a non-ionic surfactant.

9. The product of claim 1 , wherein the hydrophobically-modified polymer solution in the first compartment comprises an organic acid, wherein the organic acid is selected from acetic acid, lactic acid, ascorbic acid, and citric acid.

10. The product of claim 9 , wherein the hydrophobically-modified polymer solution in the first compartment comprises from about 0.5 to about 2M acetic acid in water.

11. The product of claim 1 , comprising a sodium bicarbonate solution in the second container.

12. A method for treating a wound in a body cavity of a mammal, comprising: releasing contents of the product of claim 1 into a cavity comprising the wound.

13. The method of claim 12 , wherein the wound is a non-compressible hemorrhage.

14. A hemostatic product comprising a container having at least two compartments each containing a releasable, flowable product: wherein a first compartment comprises a solution having a concentration from about 0.1 wt % to about 5 wt % of an acidified cationic hydrophobically-modified chitosan that creates hemostasis and has a pH of from about 2 to about 4.5, and a second compartment comprises a solution of a bicarbonate or carbonate salt at an alkaline pH and an anionic polymer, wherein the hydrophobic modifications of the chitosan comprise linear hydrocarbon groups in the range of C6 to C18.

15. A method of treating a bleeding wound, comprising: releasing contents of the product of claim 14 to the bleeding wound.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 26, 2023
From: MEDCURA, INC.
To: UNITED STATES GOVERNMENT
Reel/Frame 064620/0977 →
Continuity (2)
Provisional Application 62910080 · Oct 3, 2019
Related Publication 20220347341A1 · Nov 3, 2022
References Cited (20)
US 8668899B2 · Dowling et al. · 2014 [cited by applicant]
US 8932560B2 · Dowling et al. · 2015 [cited by applicant]
US 9066885B2 · Raghavan et al. · 2015 [cited by applicant]
US 9616088B2 · Diehn et al. · 2017 [cited by applicant]
US 10179145B2 · Dowling et al. · 2019 [cited by applicant]
US 10493094B2 · Diehn et al. · 2019 [cited by applicant]
US 11274194B2 · Dowling · 2022 [cited by applicant]
US 11298517B2 · Dowling et al. · 2022 [cited by applicant]
US 11787922B2 · Dowling · 2023 [cited by applicant]
US 20100135915A1 · Greener · 2010 [cited by applicant]
US 20190083676A1 · Zilberman et al. · 2019 [cited by applicant]
WO 2008076407A2 · 2008 [cited by applicant]
WO 2013043687A2 · 2013 [cited by applicant]
WO 2018184021A1 · 2018 [cited by applicant]
WO 2020181015A1 · 2020 [cited by applicant]
International Search Report and Written Opinion of corresponding International Application No. PCT/US20/54268 dated Jan. 12, 2021, 8 pages. [cited by applicant]
Nehache et al., “Anti-Bioadhesive Coating Based on Easy to Make Pseudozwitterionic RAFT Block Copolymers for Blood-Contacting Applications,” Macromol Biosci. 2016, pp. 57-62. [cited by applicant]
Dowling, et al., “Hydrophobically-modified chitosan foam: description and hemostatic efficacy”, J Surg Res. Jan. 2015; 193(1):316-23. doi: 10.1016/j.jss.2014.06.019. Epub Jun. 14, 2014. [cited by applicant]
Logun, et al., “Expanding Hydrophobically Modified Chitosan Foam for Internal Surgical Hemostasis: Safety Evaluation in a Murine Model”, J Surg Res. Jul. 2019;239:269-277. doi: 10.1016/j.jss.2019.01.060. Epub Mar. 16, 2… [cited by applicant]
Dowling, et al., “Sprayable Foams Based on an Amphiphilic Biopolymer for Control of Hemorrhage Without Compression”, ACS Biomater Sci Eng. Jun. 8, 2015;1(6):440-447. doi: 10.1021/acsbiomaterials.5b00067. Epub May 2, 201… [cited by applicant]